Histogenics Corporation (NASDAQ:HSGX) and Vascular Biogenics Ltd. (NASDAQ:VBLT), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of the two firms.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Histogenics Corporation	N/A	0.00	8.52M	-0.43	0.00
Vascular Biogenics Ltd.	14.31M	3.91	10.28M	-0.40	0.00

Demonstrates Histogenics Corporation and Vascular Biogenics Ltd. earnings per share, top-line revenue and valuation.

Profitability

Table 2 has Histogenics Corporation and Vascular Biogenics Ltd.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Histogenics Corporation	0.00%	66.4%	-73.3%
Vascular Biogenics Ltd.	-71.84%	-23.2%	-19.9%

Volatility and Risk

Histogenics Corporation is 252.00% more volatile than S&P 500 due to its 3.52 beta. Vascular Biogenics Ltd.’s -0.13 beta is the reason why it is 113.00% less volatile than S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Histogenics Corporation are 0.7 and 0.7. Competitively, Vascular Biogenics Ltd. has 10.4 and 10.4 for Current and Quick Ratio. Vascular Biogenics Ltd.’s better ability to pay short and long-term obligations than Histogenics Corporation.

Analyst Recommendations

Histogenics Corporation and Vascular Biogenics Ltd. Ratings and Recommendations are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Histogenics Corporation	0	1	0	2.00
Vascular Biogenics Ltd.	0	1	1	2.50

On the other hand, Vascular Biogenics Ltd.’s potential upside is 92.31% and its average price target is $3.

Insider and Institutional Ownership

Roughly 16.1% of Histogenics Corporation shares are held by institutional investors while 32.2% of Vascular Biogenics Ltd. are owned by institutional investors. Insiders held roughly 9.2% of Histogenics Corporation’s shares. On the other hand, insiders held about 26.6% of Vascular Biogenics Ltd.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Histogenics Corporation	-9.33%	-42.55%	-77.87%	-95.35%	-95.4%	35.18%
Vascular Biogenics Ltd.	7%	27.38%	39.57%	-2.73%	-73.03%	65.46%

For the past year Histogenics Corporation has weaker performance than Vascular Biogenics Ltd.

Summary

Vascular Biogenics Ltd. beats Histogenics Corporation on 7 of the 10 factors.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The companyÂ’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer. The companyÂ’s pipeline candidates also comprise VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel.